All News

Martin Schoen, MD, PhD, discusses key factors clinicians should consider when interpreting comparative real-world evidence for ARPI selection.

In this Q&A, Shiv B. Patel, MD, reflects on how prostate cancer screening has evolved from a one-size-fits-all approach to a more individualized strategy.

The target enrollment goal has been reached in the phase 3 BiPASS study, evaluating PSMA-PET plus MRI for prostate cancer detection.

Routine cardiovascular specialist referral improved cholesterol control in patients with prostate cancer but did not reduce cardiovascular events.

LUGPA CEO Celeste Kirschner, CAE, MHSA, outlines the association's top 2027 priorities: fee schedule reform, site-neutral payments, prior authorization, and practice consolidation.

Martin Schoen, MD, PhD, discusses how clinicians can interpret comparative real-world evidence and indirect analyses when head-to-head ARPI data are unavailable.

Closing racial disparities in prostate cancer requires meeting men in barbershops, churches, and community screenings—not just clinics, according to Justin Cohen, MD.

A recap of the FDA submissions and regulatory decisions in urology from August 2026.

Prof Declan Murphy discusses PROTEUS pathologic responses with apalutamide plus ADT and their implications for future treatment strategies.

Timothy D. McClure, MD, discusses 2-year PRESERVE trial safety data and 12-month AUA findings linking prostate size to IPSS improvement after focal IRE.

Mary Dunn, MSN, RN, NP-C, OCN, discusses how APPs support genetic testing through patient counseling, test ordering, result communication, and referrals to genetics specialists.

The FDA has granted clearance to a phase 1 trial of ADI-212, a PSMA-targeted, gene-edited, armored cell therapy candidate under development for mCRPC.

University of Florida urology chiefs Miranda Eubank, MD; Trisha Nguyen, MD; and Jordan Matthews-Smith, MD, reflect on residency milestones, mentorship, community, and lessons learned along the way.

This FAQ outlines what the State of Men's Health Act would do, how a federal Office of Men’s Health could affect research and clinical care, and what urologists can do to support the effort.

Emanuele Crupi, MD, discusses prospective data supporting GemFLP as a benchmark for treatment of advanced urachal and non-urachal urinary tract adenocarcinomas.

A TRUMPET registry analysis found that initial disease presentation and family history were associated with survival outcomes in metastatic castration-resistant prostate cancer.

Nicole L. Miller, MD, FACS, discusses how to distinguish bladder dysfunction from persistent obstruction when evaluating LUTS after BPH treatment.

Andrew J. Hung, MD, discusses an AI system that analyzes surgical gestures and identifies technique patterns linked to erectile function recovery after prostatectomy.

Datopotamab deruxtecan will be assessed alone and in combination with rilvegostomig as adjuvant treatment for patients with high-risk muscle-invasive urothelial carcinoma.

Host Amy Pearlman, MD, speaks with emergency physician Jeff Myers, DO, about his transition to sexual medicine and the importance of sexual health across specialties.

Davis Viprakasit, MD, FACS, discusses advanced cystoscopy training for APPs and the importance of collaboration between APPs and urologists to expand patient care.

A national cohort study found that metabolic syndrome and its components were frequently documented within the first year of concurrent ADT and ARPI therapy for prostate cancer.

Clinicians across four cities weigh ARASEC and ARANOTE trial data, drug interactions, and access barriers in mCSPC treatment decisions.

María Natalia Gandur Quiroga, MD, MSc, highlights treatment selection, negative trials, and implementation in GU oncology as 3 key themes emerging from ASCO 2026.

The phase 2 MODeFIRe-1 trial will evaluate investigational MRT-2359 plus apalutamide in AR-mutated metastatic castration-resistant prostate cancer.

Tyler Seibert, MD, PhD, discusses cribriform and intraductal carcinoma and their implications for risk stratification and treatment selection in prostate cancer.

Water vapor thermal therapy also provided greater QoL improvement vs combination pharmacotherapy while preserving sexual function.

Urology practices should prepare for more than a simple payment cut in 2027, according to Jonathan Rubenstein, MD; and Mark Painter.